Bioinformatics in in-Vitro Diagnostics (IVD) Testing Market Report 2026

The bioinformatics in in-vitro diagnostics (ivd) testing market size has grown strongly in recent years. It will grow from $98.89 billion in 2025 to $105.59 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to growth of molecular diagnostic testing volumes, increasing adoption of next-generation sequencing in diagnostics, expansion of centralized diagnostic laboratories, availability of advanced diagnostic hardware, rising use of data-driven clinical decision support.

The bioinformatics in in-vitro diagnostics (ivd) testing market size is expected to see strong growth in the next few years. It will grow to $133.49 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, expansion of personalized medicine diagnostics, rising investments in ai-enabled diagnostic platforms, growing use of cloud-based diagnostic analytics, increasing regulatory acceptance of digital diagnostics. Major trends in the forecast period include increasing use of AI-based diagnostic interpretation software, rising adoption of cloud-enabled ivd bioinformatics platforms, growing integration of molecular and clinical data sets, expansion of companion diagnostics analytics, enhanced focus on real-time diagnostic data processing.

The rising prevalence of cancer is expected to drive the growth of bioinformatics in the IVD testing market going forward. Cancer refers to a group of diseases characterized by abnormal cell growth that can invade and spread to other parts of the body. The increasing prevalence of cancer is attributed to various factors, including exposure, lifestyle, and environmental influences. Bioinformatics in IVD testing enhances cancer diagnostics by offering precise, personalized, and comprehensive genetic insights that improve early detection, treatment decisions, and patient outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that over 35 million new cancer cases are projected by 2050. Thus, the growing prevalence of cancer is driving the bioinformatics in the IVD testing market.

Major companies operating in the bioinformatics segment of the IVD testing market are concentrating on developing innovative solutions such as next-generation sequencing (NGS) technology to improve the detection and analysis of genetic mutations, enhance diagnostic accuracy, and support personalized medicine strategies. Next-generation sequencing (NGS) is a high-throughput technology that enables rapid sequencing of entire genomes or specific DNA and RNA regions, allowing for comprehensive genetic analysis. For example, in January 2024, QIAGEN Digital Insights, the bioinformatics division of the Netherlands-based molecular diagnostics company QIAGEN, introduced LightSpeed, an ultra-fast NGS secondary-analysis software accelerator integrated into its CLC Genomics Workbench Premium platform. The LightSpeed module enables laboratories to process somatic cancer NGS data at exceptional speed, converting raw sequencing files (FASTQ) into variant calls (VCF) within minutes, while lowering the cost per sample. LightSpeed supports high-throughput cancer panels and is compatible with both cloud-based and on-premises workflows, allowing bioinformatics teams to rapidly analyze multiple tumor genes and biomarkers from a single sample to guide precision oncology decision-making.

In September 2024, QIAGEN N.V., a Germany-based molecular diagnostics company, partnered with Eli Lilly and Company to develop the first IVD for APOE genotyping. This collaboration aims to introduce the first IVD for APOE genotyping in Alzheimer’s, utilizing QIAGEN’s QIAstat-Dx platform. It represents a new clinical application in neurodegenerative disease diagnostics and expands QIAGEN’s collaborations in diagnostic development. Eli Lilly and Company is a US-based pharmaceutical company specializing in In-Vitro Diagnostics Testing (IVD).

Major companies operating in the bioinformatics in in-vitro diagnostics (ivd) testing market are Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN N.V, Agilent Technologies Inc, PerkinElmer Inc, Roche Holding AG, BGI Genomics Co Ltd, DNAnexus Inc, Seven Bridges Genomics Inc, Dassault Systèmes SE (BIOVIA), Genedata AG, Partek Inc, Data4Cure Inc, Ontoforce NV, Geneious (Biomatters), SoftGenetics LLC, Eagle Genomics Ltd, Wuxi NextCODE Genomics, Bio‑Rad Laboratories Inc, Eurofins Scientific SE.

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (ivd) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioinformatics in in-vitro diagnostics (ivd) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the bioinformatics in IVD testing market by increasing costs of imported diagnostic hardware, data processing systems, analytical software, and cloud infrastructure components. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to reliance on imported high-end diagnostic equipment, while Asia-Pacific faces higher costs for exporting integrated diagnostic solutions. These tariffs are increasing implementation costs and slowing digital diagnostic adoption. At the same time, they are encouraging regional software development, local data processing infrastructure, and domestic manufacturing of diagnostic hardware systems.

The bioinformatics in in-vitro diagnostics (ivd) testing market research report is one of a series of new reports that provides bioinformatics in in-vitro diagnostics (ivd) testing market statistics, including bioinformatics in in-vitro diagnostics (ivd) testing industry global market size, regional shares, competitors with a bioinformatics in in-vitro diagnostics (ivd) testing market share, detailed bioinformatics in in-vitro diagnostics (ivd) testing market segments, market trends and opportunities, and any further data you may need to thrive in the bioinformatics in in-vitro diagnostics (ivd) testing industry. This bioinformatics in in-vitro diagnostics (ivd) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioinformatics in in vitro diagnostics (IVD) involves the use of computational techniques, data analysis, and software tools to interpret and examine biological data produced by in vitro diagnostic tests. It includes applying algorithms and statistical models to handle large amounts of molecular and clinical data obtained from diagnostic tests performed outside the living organism (in vitro).

The main categories of bioinformatics in in vitro diagnostics (IVD) testing are hardware and software. Bioinformatics in IVD testing hardware pertains to the physical equipment and devices utilized in laboratory and computational environments. The types of tests include blood-based tests and tissue-based tests. These tests are applied in various areas such as cardiovascular diseases, chronic diseases, diabetes, cancer, and more.

The bioinformatics in in-vitro diagnostics (IVD) testing market consists of revenues earned by entities by providing services such as clinical decision support systems, sequence analysis, and clinical genomics software. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioinformatics in in vitro diagnostics (IVD) testing market also includes sales of sequencing tools and diagnostics tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.